2.115

9.19% 0.205

Cytomx Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

Cytomx Therapeutics Inc stock is traded at $2.115, with a volume of 6.68M. It is up +9.19% in the last 24 hours and down -12.56% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Previous Close:

$1.91

Open:

$1.95

24h Volume:

6.68M

Relative Volume:

2.18

Market Cap:

$347.97M

Revenue:

$101.21M

Net Income/Loss:

$-569.00K

P/E Ratio:

-105.75

EPS:

-0.02

Net Cash Flow:

$-56.88M

1W Performance:

-9.72%

1M Performance:

-12.56%

6M Performance:

+162.26%

1Y Performance:

+73.79%

1-Day Range:

$1.90

$2.12

1-Week Range:

$1.72

$2.265

52-Week Range:

$0.40

$3.095

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name

Cytomx Therapeutics Inc

Sector

Healthcare (1159)

Industry

Biotechnology (645)

Phone

650.515.3185

Address

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

121

Twitter

@cytomxinc

Next Earnings Date

2024-11-07

Latest SEC Filings

CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTMX Cytomx Therapeutics Inc	2.11	314.98M	101.21M	-569.00K	-56.88M	-0.02
VRTX Vertex Pharmaceuticals Inc	389.81	100.71B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	576.33	61.52B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	456.52	58.84B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.28	40.01B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.20	38.20B	3.81B	-644.79M	-669.77M	-6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Initiated	Oppenheimer	Outperform
May-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-14-25	Resumed	Piper Sandler	Overweight
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight
May-09-24	Upgrade	Wedbush	Neutral → Outperform
May-06-24	Upgrade	Jefferies	Hold → Buy
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

08:26 AM

CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN

08:26 AM

04:25 AM

Is This the Dip to Buy in CytomX Therapeutics Inc.Breakout Watch & Expert Approved Trade Ideas - classian.co.kr

04:25 AM

Aug 17, 2025

Intraday Charts Show Spike in CytomX Therapeutics Inc. ActivityGap Down & Advanced Swing Trade Entry Plans - sundaytimes.kr

Aug 17, 2025

Aug 16, 2025

CytomX Therapeutics Inc. stock trend forecastSwing Trade & High Conviction Investment Ideas - Newser

Aug 16, 2025

Is this a good reentry point in CytomX Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - Newser

Aug 16, 2025

News impact scoring models applied to CytomX Therapeutics Inc.2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser

Aug 16, 2025

What institutional flow reveals about CytomX Therapeutics Inc.July 2025 Drop Watch & Daily Market Momentum Tracking - Newser

Aug 16, 2025

Analyzing CytomX Therapeutics Inc. with multi timeframe chartsPortfolio Risk Report & Safe Swing Trade Setup Alerts - Newser

Aug 16, 2025

Aug 15, 2025

Identifying reversal signals in CytomX Therapeutics Inc.Weekly Profit Analysis & Weekly Market Pulse Alerts - Newser

Aug 15, 2025

Technical analysis overview for CytomX Therapeutics Inc. stockJuly 2025 Pullbacks & Long-Term Growth Plans - Newser

Aug 15, 2025

What makes CytomX Therapeutics Inc. stock price move sharplyShare Buyback & High Return Trade Guides - sundaytimes.kr

Aug 15, 2025

CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest

Aug 15, 2025

Is CytomX Therapeutics Inc. stock poised for growth2025 Technical Overview & Community Consensus Picks - Newser

Aug 15, 2025

FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares Boosts Biotech Portfolio - AInvest

Aug 15, 2025

Aug 14, 2025

RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it

Aug 14, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN

Aug 14, 2025

Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN

Aug 14, 2025

Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals

Aug 14, 2025

Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st

Aug 14, 2025

Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛

Aug 14, 2025

Is CytomX Therapeutics Inc. reversing from oversold territory2025 Key Highlights & Community Verified Swing Trade Signals - Newser

Aug 14, 2025

What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World

Aug 14, 2025

Aug 13, 2025

CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com Nigeria

Aug 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛

Aug 13, 2025

CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks

Aug 13, 2025

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus

Aug 13, 2025

CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria

Aug 13, 2025

CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener

Aug 13, 2025

CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView

Aug 13, 2025

CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan

Aug 13, 2025

HC Wainwright Issues Pessimistic Outlook for CTMX Earnings - Defense World

Aug 13, 2025

Aug 12, 2025

Published on: 2025-08-13 07:49:54 - sundaytimes.kr

Aug 12, 2025

Aug 11, 2025

CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks

Aug 11, 2025

Aug 10, 2025

CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest

Aug 10, 2025

CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru

Aug 10, 2025

Aug 09, 2025

CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest

Aug 09, 2025

Aug 08, 2025

CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest

Aug 08, 2025

CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha

Aug 08, 2025

CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest

Aug 08, 2025

Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - NewsBreak: Local News & Alerts

Aug 08, 2025

Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com

Aug 08, 2025